Background Febuxostat and allopurinol are urate-lowering therapies used to treat patients
with gout. Following concerns about the cardiovascular safety of febuxostat, the European …

Background Cardiovascular risk is increased in patients with gout. We compared
cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor …

Introduction Gout affects 2.5% of the UK's adult population and is now the most common
type of inflammatory arthritis. The long-term management of gout requires reduction of …

The cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout
remains equivocal. Febuxostat had a better safety outcome compared with allopurinol. In …

Objective To evaluate the safety and efficacy of febuxostat compared to allopurinol for the
treatment of chronic gout. Methods We did a systematic review and meta-analysis of …

Background and aims Systemic reviews and meta-analyses suggest hyperuricemia is a
cardiovascular risk factor. The effects of xanthine oxidase inhibitors on cardiac outcomes …

Abstract Febuxostat (Adenuric®, Uloric®, Feburic®) is an orally-active, potent, non-purine,
selective xanthine oxidase inhibitor. In the EU, it is indicated in adults for the treatment of …

Background: Hyperuricemia and gout are associated with an increased risk of
cardiovascular disease. Xanthine oxidase inhibitors, allopurinol and febuxostat, are the …

Background The relative efficacy and safety of allopurinol and febuxostat when used
according to current guidelines for the treatment of hyperuricemia are unknown. This double …

Objectives. To determine if urate-lowering treatment (ULT) in gout can reduce
cardiovascular (CV) outcomes. Methods. Randomized trials were searched for treatment …